Episteme Prognostics Inc
- Diagnostics
- Medical device or technology
Episteme Prognostics is pioneering a new paradigm in the $11 billion precision cancer diagnostics market with its breakthrough technology. Our lead product, PancEpistemeDx™, predicts chemotherapy response – the only frontline therapy - in pancreatic cancer, with 92% accuracy for responders and 99% for non-responders. With over 67K new cases annually in the U.S. and more than 500K globally, and only 13% responding to frontline chemo, this represents a major unmet need. Supported by NIH funding, active FDA engagement, and $4.1M in private equity investment from Spring Mountain Capital and Waymark Capital, we are on track to launch an LDT (Laboratory Developed Test). We are currently raising a $15M Series A round to pursue FDA De Novo clearance. With a $200M annual revenue opportunity and plans to expand into other high-need cancers, we offer investors a compelling first-mover advantage in the underserved pancreatic diagnostics market—and a clear path to acquisition or commercialization.
)
)
)
)
){kind=logo}
){kind=logo}
)
){kind=logo}
)
){kind=logo}
){kind=logo}